Skip to main content

Specialty Pharmacy

  • Pfizer on kidney cancer drug: Extends lives of patients

    NEW YORK — Pfizer got promising results from a late-stage clinical trial of a cancer treatment, the drug maker said Friday.

     

    Pfizer announced results of the phase-3 “AXIS 1032” trial of the kidney cancer drug axitinib, saying that it “significantly” extended the lives of patients with advanced renal cell carcinoma compared with Nexavar (sorafenib), made by Bayer HealthCare and Onyx Pharmaceuticals.

     

     

  • Amgen's Xgeva receives FDA approval

    SILVER SPRING, Md. — The Food and Drug Administration has approved a treatment for preventing skeletal injuries in patients whose cancer has spread to the bone.

     

    The FDA announced Friday the approval of Thousand Oaks, Calif.-based biotech company Amgen’s Xgeva (denosumab) for bone metastases.

     

     

  • Express Scripts establishes specialty benefits organization

    ST. LOUIS — Pharmacy benefit manager Express Scripts has created what it calls the industry’s most comprehensive specialty benefits organization, the company announced Thursday.

     

  • FDA panel recommends approval for lupus drug Benlysta

    ROCKVILLE, Md. A decision by a Food and Drug Administration advisory committee could pave the way for the first new drug to treat lupus in decades.

     

    The FDA’s Arthritis Advisory Committee voted 13-2 Tuesday to recommend approval for Benlysta (belimumab), a drug for systemic lupus erythematosus made by British drug maker GlaxoSmithKline and U.S.-based Human Genome Sciences, the two companies announced. Lupus is an inflammatory disorder that affects internal organs, joints and skin and, in its severest forms, can be fatal.

     

  • FDA advisory committee recommends expanded use of Gardasil

    WHITEHOUSE STATION, N.J. — A Food and Drug Administration advisory committee has recommended expanded approval of a vaccine for genital warts.

    Merck announced Wednesday that the FDA Vaccines and Related Biological Products Advisory Committee recommended approval of Gardasil (human papillomavirus quadrivalent [types 6, 11, 16 and 18] vaccine, recombinant) for males and females ages 9 to 26 years to prevent anal cancer and anal intraepithelial neoplasia, both diseases that result from infection by the human papillomavirus.

  • COPD patients express hardships in new GSK study

    RESEARCH TRIANGLE PARK, N.C. Patients living with chronic obstructive pulmonary disease said the illness prevented them from living life to its fullest, according to research conducted by drug maker GlaxoSmithKline.

     

  • Sangart granted orphan drug designation for sickle cell drug

    SAN DIEGO — The Food and Drug Administration has granted orphan drug designation to a drug for treating sickle cell disease.

     

  • Axium, Firma Medical enter ED collaboration

    LAKE MARY, Fla. A specialty pharmacy provider and a manufacturer will collaborate to provide treatments for erectile dysfunction.

     

    Axium Healthcare Pharmacy and Firma Medical announced the partnership Wednesday where by Axium’s erectile dysfunction line of injectable compounded pharmaceuticals will be marketed to Firma’s physician and patient customers around the country. The companies said the deal would give Axium broader distribution while increasing the number of treatment options for Firma’s customers.

     

X
This ad will auto-close in 10 seconds